Multiple studies have reported that protein kinase B (PKB, also known as Akt) activators can promote chemoresistance and increase the survival of ovarian cancer cells by attenuating the p53 proapoptotic signal [103]. This evidence concerns the gene AKT1 and ovarian carcinoma.